US Patent

US12447241 — Multi-unit drug delivery devices and methods

Formulation · Assigned to Taris Biomedical LLC · Expires 2034-08-19 · 8y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects implantable and intravesical drug delivery devices that release a drug, such as Gemzar, and a functional agent or excipient.

USPTO Abstract

Implantable drug delivery devices include a housing defining a reservoir, a first unit within the reservoir, and a second unit within the reservoir. The first unit contains a drug and the second unit contains a functional agent that facilitates release of the drug. Intravesical drug delivery devices include a housing portion containing a drug formulation and a housing portion containing an excipient, and are configured to release the drug according to a first release profile and the excipient according to a second release profile. Methods include inserting any of these devices into a patient and releasing drug from the device.

Drugs covered by this patent

Patent Metadata

Patent number
US12447241
Jurisdiction
US
Classification
Formulation
Expires
2034-08-19
Drug substance claim
No
Drug product claim
Yes
Assignee
Taris Biomedical LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.